| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-112 |
Sentence |
denotes |
Unfolded protein response is required in nu/nu mice microvasculature for treating breast tumor with tunicamycin. |
| T2 |
113-240 |
Sentence |
denotes |
Up-regulation of the dolichol pathway, a "hallmark" of asparagine-linked protein glycosylation, enhances angiogenesis in vitro. |
| T3 |
241-328 |
Sentence |
denotes |
The dynamic relationship between these two processes is now evaluated with tunicamycin. |
| T4 |
329-455 |
Sentence |
denotes |
Capillary endothelial cells treated with tunicamycin were growth inhibited and could not be reversed with exogenous VEGF(165). |
| T5 |
456-670 |
Sentence |
denotes |
Inhibition of angiogenesis is supported by down-regulation of (i) phosphorylated VEGFR1 and VEGFR2 receptors; (ii) VEGF(165)-specific phosphotyrosine kinase activity; and (iii) Matrigel(TM) invasion and chemotaxis. |
| T6 |
671-781 |
Sentence |
denotes |
In vivo, tunicamycin prevented the vessel development in Matrigel(TM) implants in athymic Balb/c (nu/nu) mice. |
| T7 |
782-887 |
Sentence |
denotes |
Immunohistochemical analysis of CD34 (p < 0.001) and CD144 (p < 0.001) exhibited reduced vascularization. |
| T8 |
888-1071 |
Sentence |
denotes |
A 3.8-fold increased expression of TSP-1, an endogenous angiogenesis inhibitor in Matrigel(TM) implants correlated with that in tunicamycin (32 h)-treated capillary endothelial cells. |
| T9 |
1072-1247 |
Sentence |
denotes |
Intravenous injection of tunicamycin (0.5 mg/kg to 1.0 mg/kg) per week slowed down a double negative (MDA-MB-435) grade III breast adenocarcinoma growth by ∼50-60% in 3 weeks. |
| T10 |
1248-1398 |
Sentence |
denotes |
Histopathological analysis of the paraffin sections indicated significant reduction in vessel size, the microvascular density and tumor mitotic index. |
| T11 |
1399-1459 |
Sentence |
denotes |
Ki-67 and VEGF expression in tumor tissue were also reduced. |
| T12 |
1460-1546 |
Sentence |
denotes |
A significant reduction of N-glycan expression in tumor microvessel was also observed. |
| T13 |
1547-1969 |
Sentence |
denotes |
High expression of GRP-78 in CD144-positive cells supported unfolded protein response-mediated ER stress in tumor microvasculature. ∼65% reduction of a triple negative (MDA-MB-231) breast tumor xenograft in 1 week with tunicamycin (0.25 mg/kg) given orally and the absence of systemic and/or organ failure strongly supported tunicamycin's potential for a powerful glycotherapeutic treatment of breast cancer in the clinic. |
